Alfatide[18F]

氟[18F]阿法肽

Report date: 2025/11/19 17:58:14
NME

Base Information

Drug NameAlfatide[18F]
Drug Alias NameFluorine-18-alfatideFluorine-18-AlF-NOTA-PRGD2alfatide-[18F]18F-Alphatide18F-AlF-NOTA-PRGD2 +[8] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18FRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsContrast agentsCarcinoma, Non-Small-Cell LungCarcinoma, Bronchogenic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Smk Pharmaceutical Co LtdTaizhou Kairui Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi No 4 People'S HospitalYantai Lannacheng Biotechnology Co LtdYantai Dongcheng Pharmaceutical Group Co Ltd +[5] 
Inactive CompaniesJinling Hospital,Nanjing University,School Medicine
Active IndicationsContrast agentsCarcinoma, Non-Small-Cell LungCarcinoma, Bronchogenic +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A